Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Acquisitions & Divestments: 2023-2025

Historic Change in Acquisitions & Divestments for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $29.6 million.

  • Artiva Biotherapeutics' Change in Acquisitions & Divestments rose 138.90% to $29.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.8 million, marking a year-over-year increase of 82.65%. This contributed to the annual value of $56.4 million for FY2024, which is 110.26% up from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Change in Acquisitions & Divestments is $29.6 million, which was up 4.86% from $28.2 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Change in Acquisitions & Divestments' 5-year high stood at $29.6 million during Q3 2025, with a 5-year trough of $12.0 million in Q3 2023.
  • For the 3-year period, Artiva Biotherapeutics' Change in Acquisitions & Divestments averaged around $18.7 million, with its median value being $14.0 million (2024).
  • Data for Artiva Biotherapeutics' Change in Acquisitions & Divestments shows a peak YoY surged of 138.90% (in 2025) over the last 5 years.
  • Artiva Biotherapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $12.8 million in 2023, then climbed by 8.98% to $13.9 million in 2024, then skyrocketed by 138.90% to $29.6 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $29.6 million for Q3 2025, versus $28.2 million for Q2 2025 and $29.0 million for Q1 2025.